Stock comparison
Harmony Biosciences Holdings
Vericel
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HRMY
Harmony Biosciences Holdings
Market cap
$1.75B
Sector
Healthcare
VCEL
Vericel
Market cap
$1.77B
Sector
Healthcare
Overall winner
Harmony Biosciences Holdings HRMY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HRMY | VCEL | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 52D | HRMY |
| Benjamin Graham | 60C | 69D | VCEL |
| Philip Fisher | 75B | 57C | HRMY |
| Peter Lynch | 62C | 45D | HRMY |
| Joel Greenblatt | 28F | 44D | VCEL |
| Charlie Munger | 62C | 43D | HRMY |
| Terry Smith | 67B | 52D | HRMY |
Side-by-side metrics
| Metric | HRMY | VCEL |
|---|---|---|
| Market cap | $1.75B | $1.77B |
| P/E (TTM) | 11.8x | 82.5x |
| EV/EBIT | 6.4x | 159.9x |
| ROIC (TTM) | 12.5% | 3.35% |
| Gross margin | 76.55% | 74.84% |
| Net margin | 16.2% | 7.35% |
| Revenue CAGR 5y | 29.85% | 15.32% |
| EPS CAGR 5y | 46.45% | - |
| Debt / Equity | 0.2x | 0.3x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HRMY leads on
- EV/EBIT6.4xvs 159.9x+96%
- P/E (TTM)11.8xvs 82.5x+86%
- ROIC (TTM)12.5%vs 3.35%+73%
- Net margin16.2%vs 7.35%+55%
VCEL leads on
No clear edges - the other side wins or ties on every measured metric.
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.